– USA, CO – Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced the appointment of Meghan Scanlon to its Board of Directors.
“We are very excited to have Meghan join our Board of Directors. Meghan is a seasoned global medical device executive with an impressive track record of success. Meghan is also a champion for diversity and inclusion. I look forward to partnering with Meghan to advance our mission of improving foot and ankle patient outcomes,” said CEO and Chairman, Albert DaCosta.
Ms. Scanlon has also joined the Compensation and Quality, Technology, and Regulatory Committees.
About Meghan Scanlon
Ms. Scanlon has more than 20 years of senior leadership experience with global medical device companies. She currently serves as SVP and president, of Urology and Pelvic Health, for Boston Scientific Corporation, and is a member of the Boston Scientific Executive Committee. Ms. Scanlon also is a member of the Boston Scientific Global Council for Inclusion, serving as the executive sponsor for the PRIDE employee resource group.
Before Boston Scientific, Ms. Scanlon worked at DePuy Synthes, the orthopedics company of Johnson & Johnson, from July 2000 to September 2014. Ms. Scanlon holds a B.S. in Mechanical Engineering from Tufts University, and both an M.B.A and an M.S. in Mechanical Engineering from the Massachusetts Institute of Technology.
About Paragon 28, Inc.
Based in Englewood, Colo., Paragon 28, is a leading medical device company exclusively focused on the foot and ankle orthopedic market and is dedicated to improving patient lives. From the onset, Paragon 28® has provided innovative orthopedic solutions, procedural approaches, and instrumentation that cover a wide range of foot and ankle ailments including fracture fixation, hallux valgus (bunions), hammertoe, ankle, progressive collapsing foot deformity or flatfoot, Charcot foot, and orthobiologics. The company designs products with both the patient and surgeon in mind, to improve outcomes, reduce ailment recurrence and complication rates, and make the procedures simpler, consistent, and reproducible.
For more information: https://paragon28.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
